Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES H SCHULTZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1356376164
CMS profile
658220
Location
ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,863.08

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $3,527.47 3
Food and Beverage $335.61 4

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Chiesi USA, Inc. $2,134.06 2
Shionogi Inc $1,681.09 3
AbbVie Inc. $31.25 1
AstraZeneca Pharmaceuticals LP $16.68 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES H SCHULTZ

NPI 1356376164 · CMS profile ID 658220

Allopathic & Osteopathic Physicians / Family Medicine

ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356376164?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356376164?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356376164?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356376164?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $3,863.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Shionogi Inc $1,213.3309/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051759849 CMS
Shionogi Inc $176.4509/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051759853 CMS
Shionogi Inc $291.3109/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051759857 CMS
AstraZeneca Pharmaceuticals LP $16.6808/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015415887 CMS
AbbVie Inc. $31.2507/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998878741 CMS
Chiesi USA, Inc. $2,022.8301/28/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050864265 CMS
Chiesi USA, Inc. $111.2301/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050864259 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.18 3
PY2020 $63.02 3
PY2021 $1,574.29 2
PY2022 $55.88 3
PY2023 $3,863.08 7
PY2024 $2,152.07 33
PY2025 $1,055.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $659,253.73 104
PY2024 Recipient $48,637.04 5
PY2024 Principal investigator $695,064.02 430
PY2023 Recipient $11,583.04 6
PY2023 Principal investigator $285,021.08 179
PY2022 Recipient $96,487.00 3
PY2022 Principal investigator $144,410.00 2
PY2020 Principal investigator $92,548.80 14
PY2019 Principal investigator $639,103.36 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

104 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $150.00 12/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213706142
Principal investigator 1 Novo Nordisk AS $5,215.00 12/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213760053
Principal investigator 1 Novo Nordisk AS $900.00 12/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213804006
Principal investigator 1 Abbott Laboratories $29,547.50 12/10/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248160402
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 12/03/2025 Non-covered Recipient Entity
Neighborhood Healthcare
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $390.00 12/03/2025 Non-covered Recipient Entity
Neighborhood Healthcare
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508626
Principal investigator 1 Novo Nordisk AS $600.00 11/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213741655
Principal investigator 1 Novo Nordisk AS $1,160.00 11/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213758097
Principal investigator 1 Indivior Inc. $320.00 11/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469093
Principal investigator 1 Indivior Inc. $48.00 11/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240469095
Principal investigator 1 Abbott Laboratories $47,820.00 11/13/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248160400
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,000.00 11/05/2025 Non-covered Recipient Entity
Neighborhood Healthcare
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 11/05/2025 Non-covered Recipient Entity
Neighborhood Healthcare
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508632
Principal investigator 1 Novo Nordisk AS $150.00 10/29/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213712382
Principal investigator 1 Novo Nordisk AS $4,548.00 10/29/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213729055
Principal investigator 1 Indivior Inc. $144.00 10/10/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468979
Principal investigator 1 Indivior Inc. $187.25 10/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468847
Principal investigator 1 Indivior Inc. $347.50 10/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468849
Principal investigator 1 Indivior Inc. $187.25 10/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468851
Principal investigator 1 Indivior Inc. $187.25 10/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468853
Principal investigator 1 Abbott Laboratories $6,120.65 09/24/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248156204
Principal investigator 1 Novo Nordisk AS $3,370.00 09/19/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213784407
Principal investigator 1 Indivior Inc. $256.00 09/03/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468363
Principal investigator 1 Indivior Inc. $320.00 09/03/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468365
Principal investigator 1 Abbott Laboratories $285.00 08/25/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157726
Principal investigator 1 Abbott Laboratories $658.95 08/25/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248157728
Principal investigator 1 Novo Nordisk AS $250.00 08/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213734619
Principal investigator 1 Novo Nordisk AS $7,669.00 08/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213735029
Principal investigator 1 Novo Nordisk AS $1,050.00 08/22/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213776954
Principal investigator 1 Indivior Inc. $347.50 08/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468265
Principal investigator 1 Indivior Inc. $187.25 08/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468267
Principal investigator 1 Indivior Inc. $187.25 08/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468269
Principal investigator 1 Indivior Inc. $187.25 08/20/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468271
Principal investigator 1 Indivior Inc. $288.00 08/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467907
Principal investigator 1 Indivior Inc. $94.00 08/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467909
Principal investigator 1 Indivior Inc. $187.25 07/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467485
Principal investigator 1 Indivior Inc. $187.25 07/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467487
Principal investigator 1 Indivior Inc. $187.25 07/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467489
Principal investigator 1 Indivior Inc. $187.25 07/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467491
Principal investigator 1 Novo Nordisk AS $5,886.00 07/16/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213723309
Principal investigator 1 Indivior Inc. $358.00 07/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467379
Principal investigator 1 Indivior Inc. $350.00 07/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467381
Principal investigator 1 Indivior Inc. $314.00 07/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467383
Principal investigator 1 Novo Nordisk AS $3,724.00 06/30/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213789535
Principal investigator 1 Novo Nordisk AS $450.00 06/30/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213838279
Principal investigator 1 Indivior Inc. $347.50 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467179
Principal investigator 1 Indivior Inc. $187.25 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467181
Principal investigator 1 Indivior Inc. $347.50 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467183
Principal investigator 1 Indivior Inc. $187.25 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467185
Principal investigator 1 Indivior Inc. $347.50 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467187
Principal investigator 1 Indivior Inc. $187.25 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467189
Principal investigator 1 Indivior Inc. $187.25 06/26/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467191
Principal investigator 1 Abbott Laboratories $1,425.00 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153972
Principal investigator 1 Abbott Laboratories $2,196.50 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153974
Principal investigator 1 Abbott Laboratories $35.00 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153978
Principal investigator 1 Abbott Laboratories $12.00 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153980
Principal investigator 1 Abbott Laboratories $20.00 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153982
Principal investigator 1 Abbott Laboratories $90.00 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153984
Principal investigator 1 Abbott Laboratories $18.99 06/12/2025 Non-covered Recipient Entity
Neighborhood Healthcare
ISM2512032A-Observation and Identification of Glycemic Metrics and Patterns in People with and without Prediabetes (PREMAP) No dispute reported 06/30/2026 1248153986
Principal investigator 1 Indivior Inc. $187.25 05/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466461
Principal investigator 1 Indivior Inc. $187.25 05/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466463
Principal investigator 1 Indivior Inc. $187.25 05/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466465
Principal investigator 1 Indivior Inc. $187.25 05/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466467
Principal investigator 1 Novo Nordisk AS $450.00 05/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213713516
Principal investigator 1 Novo Nordisk AS $4,716.00 05/21/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213754296
Principal investigator 1 Indivior Inc. $94.00 05/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466177
Principal investigator 1 Indivior Inc. $94.00 05/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466179
Principal investigator 1 Indivior Inc. $288.00 05/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466181
Principal investigator 1 Indivior Inc. $304.00 05/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466183
Principal investigator 1 Indivior Inc. $1,500.00 05/14/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240466185
Principal investigator 1 Indivior Inc. $187.25 04/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465897
Principal investigator 1 Indivior Inc. $187.25 04/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465899
Principal investigator 1 Indivior Inc. $347.50 04/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465901
Principal investigator 1 Indivior Inc. $347.50 04/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465903
Principal investigator 1 Indivior Inc. $187.25 04/23/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465905
Principal investigator 1 Novo Nordisk AS $1,050.00 04/21/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213727884
Principal investigator 1 Novo Nordisk AS $5,322.50 04/21/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213748727
Principal investigator 1 Indivior Inc. $347.50 04/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465403
Principal investigator 1 Indivior Inc. $187.25 04/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465405
Principal investigator 1 Indivior Inc. $187.25 04/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465407
Principal investigator 1 Indivior Inc. $187.25 04/02/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465409
Principal investigator 1 Novo Nordisk AS $4,515.00 03/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213715949
Principal investigator 1 Novo Nordisk AS $800.00 03/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213734806
Principal investigator 1 Indivior Inc. $347.50 03/03/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464762
Principal investigator 1 Indivior Inc. $187.25 03/03/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464764
Principal investigator 1 Indivior Inc. $187.25 03/03/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464766
Principal investigator 1 Novo Nordisk AS $5,128.00 02/21/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213748645
Principal investigator 1 Indivior Inc. $292.00 02/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463769
Principal investigator 1 Indivior Inc. $94.00 02/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463771
Principal investigator 1 Novo Nordisk AS $2,732.00 02/05/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE GRAND AVENUE
NN9536-4512 No dispute reported 06/30/2026 1213843948
Principal investigator 1 Eli Lilly and Company $41,699.00 02/04/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187885426
Principal investigator 1 Eli Lilly and Company $570.00 01/31/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187885430
Principal investigator 1 Eli Lilly and Company $325.00 01/31/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187885648
Principal investigator 1 Indivior Inc. $187.25 01/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463533
Principal investigator 1 Indivior Inc. $187.25 01/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463535
Principal investigator 1 Indivior Inc. $187.25 01/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463537
Principal investigator 1 Indivior Inc. $347.50 01/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463539
Principal investigator 1 Indivior Inc. $347.50 01/28/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463543
Principal investigator 1 Eli Lilly and Company $877.69 01/27/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187884412
Principal investigator 1 Eli Lilly and Company $7,438.20 01/27/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187886562
Principal investigator 1 Eli Lilly and Company $23,515.00 01/17/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1187886560
Principal investigator 1 Eli Lilly and Company $26,437.00 01/13/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) No dispute reported 06/30/2026 1187886558
Principal investigator 1 Eli Lilly and Company $269,673.00 01/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187884410
Principal investigator 1 Eli Lilly and Company $115,255.00 01/07/2025 Non-covered Recipient Entity
NEIGHBORHOOD HEALTHCARE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187885646